申请人:MedImmune Oncology, Inc.
公开号:US20020107393A1
公开(公告)日:2002-08-08
The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group Poverscore (1)} (#2) and having a triclinic cell with dimensions of about a=7.699 Å, b=9.606 Å and c=13.012 Å is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline, is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form.
本发明提供了2,4-二
氨基-5-甲基-6-[(
3,4,5-三甲氧基苯胺基)甲基
]喹嗪或三甲
嘧啶的热稳定形式。本发明揭示了属于空间群P1(#2)的三斜晶胞,尺寸约为a=7.699Å,b=9.606Å和c=13.012Å的2,4-二
氨基-5-甲基-6-[(
3,4,5-三甲氧基苯胺基)甲基
]喹嗪单
水合物或三甲
嘧啶单
水合物。本发明还揭示了一种新的席夫碱化合物,2,4-二
氨基-5-甲基-6-[(3,4,5-三
甲氧基苯亚胺基)-甲烯基
]喹嗪。本发明还提供了生产稳定的三甲
嘧啶游离碱化合物的新方法,包括结晶三甲
嘧啶单
水合物。晶体单
水合物形式提供了比无
水形式更高的稳定性。